Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets

Table 1 Baseline clinicopathological characteristics of the combined cohort

		METABRIC (N = 702)		TCGA (N = 330)		MSK-IMPACT (N = 548)		Total (N = 1580)
		N	%	N	%	N	%	N	%
Histology*	ILC	76	10.8	100	30.3	103	18.8	279	17.7
Histology*	IDC	626	89.2	230	69.7	445	81.2	1301	82.3
Age	< 50 years	125	17.8	87	26.4	190	34.7	402	25.4
Age	≥ 50 years	577	82.2	243	73.6	358	65.3	1178	74.6
Menopause	Pre-	125	17.8	90	27.2	234	42.7	449	28.5
	Post-	577	82.2	219	66.4	309	56.4	1105	69.9
	unknown	0	0	21	6.4	5	0.9	26	1.6
Stage*	I	238	33.9	67	49.3	270	49.3	575	36.4
	II	418	59.5	188	34.3	188	34.3	794	50.3
	III	46	6.6	75	16.4	90	16.4	211	13.4
Tumor size	< 20 mm	215	30.6	96	29.1	330	60.2	641	40.6
Tumor size	≥ 20 mm	487	69.4	234	70.9	218	39.8	939	59.4
Tumor grade	1	61	8.7	49	14.8	51	9.3	161	10.2
	2	344	49.0	190	57.6	191	34.9	725	45.9
	3	268	38.2	81	24.5	288	52.6	637	40.3
	Unknown	29	4.1	10	3.0	18	3.3	57	3.6
Follow-up	< 5 years	137	19.5	261	82.8	454	82.8	852	53.9
	5–10 years	195	27.8	61	11.7	64	11.7	320	20.3
	≥ 10 years	370	52.7	8	5.5	30	5.5	408	25.8
Status	Alive**	310	44.2	299	90.1	494	90.1	1103	69.8
Status	Deceased	392	55.8	31	9.9	54	9.9	477	20.3

*Cases of ILC/IDC histology, stage I–III, ER+ and HER2− status with clinical outcome and mutational data were selected via CBioportal
**At last follow-up

ISSN: 1465-542X